“The U.S. Food and Drug Administration on Tuesday gave the nod to the first of a new class of medications against dry eye disease. Xiidra (lifitegrast) eyedrops are a newly developed type of drug called LFA-1 agonists, the agency explained in a news release.”
“Xiidra’s safety and effectiveness was assessed in more than 1,000 adults in four separate clinical trials. Patients received either Xiidra eyedrops or a placebo eyedrop twice daily for three months. According to the FDA, people taking Xiidra gained more improvement in “both the signs and the symptoms of eye dryness” compared to those taking the placebo.Side effects included eye irritation, blurred vision and “an unusual taste sensation,” the FDA said. Xiidra is made by Shire US, of Lexington, Mass.”
Read the full article: FDA Approves First of New Drugs for Dry Eye
Recent Posts
- Protected: The American Health Council Appoints Mr. Eric Cox, MPT, to the Physical Therapy Board February 13, 2019
- Protected: The American Health Council Appoints Mr. Adam Hait, RPh, to the Industry Board February 12, 2019
- Protected: The American Health Council Appoints Ms. Mariana Viera-Navarro to the Physician Board February 11, 2019
- Protected: The American Health Council Appoints Ms. Shayla Schneider, BS, RPh to the Industry Board February 1, 2019
- Protected: The American Health Council Appoints Mrs. Tiffany Cossey MCD, CCC-SLP to the Industry Board February 1, 2019
- Protected: The American Health Council Appoints Ms. Charlie Evans, RPT, MHA to the Physical Therapy Board February 1, 2019
